EXTON, Pa., March 8, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) fourth quarter and year end financial results for 2004 and guidance for 2005 are expected to be released on Thursday, March 10, 2005 at the close of the U.S. financial markets.
The company will host a conference call and live audio webcast at 10:00 a.m. eastern time the following morning, Friday March 11, 2005. During the conference call, ViroPharma management will discuss the 2004 financial results and other business, including a discussion of the guidance for 2005.
The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until March 25, 2005. To participate in the conference call, please dial (800) 811-0667 (domestic) and (913) 981-4901 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.
About ViroPharma Incorporated
ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(r) Pulvules(r), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/pulvules_pi.pdf). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at www.viropharma.com.